Total liabilities of STAAR Surgical Company – HAM:SR3
This page displays financial information for STAAR Surgical Company (HAM:SR3), specifically focusing on its total liabilities. The content appears to be a stub or a section of a larger financial data platform, showing headings for "Period," "Value," "Change," and "Change %" but without actual data filled in.
Stocks making big moves this week: Bally's, Adobe, Novavax, Semtech, and STAAR Surgical
This article highlights several stocks that made significant movements this week, including Bally's, Adobe, Novavax, Semtech, and STAAR Surgical. Bally's rose due to a potential sale of development rights, Adobe increased after BlackRock raised its stake, and Novavax saw gains following positive trial results from peers. Semtech's stock climbed after selling its cellular module business, while STAAR Surgical experienced a decline due to underwhelming second-quarter earnings.
Madison Avenue Partners, LP Buys Staar Surgical Co (STAA) -- Shares Look 31% Undervalued on GF Value
Madison Avenue Partners, LP significantly increased its stake in Staar Surgical Co (STAA) by purchasing an additional 1,321,038 shares at $28.69 each, bringing its total holdings to 4,175,748 shares. This transaction, executed on June 30, 2026, represents a 1.62% portfolio impact and suggests Madison Avenue Partners believes in STAA's long-term intrinsic value despite a recent 19.64% decline in the stock price since the purchase. GuruFocus data classifies STAA as a "Possible Value Trap, Think Twice" but notes its GF Value of $33.51 indicates it is trading at a discount to its estimated intrinsic value.
5 Insightful Analyst Questions From STAAR Surgical’s Q2 Earnings Call
STAAR Surgical's Q2 results exceeded analyst expectations for revenue and adjusted earnings, driven by increased adoption of EVO Plus in China and market share gains. Despite the positive financial performance, the market reacted negatively, raising questions about growth sustainability. The article highlights key analyst questions and management responses regarding Q3 expectations, China growth, U.S. strategy, competition, and pricing power.
STAAR Surgical (STAA) links CEO options to $50–$100 hurdles
STAAR Surgical (STAA) has granted its President and CEO, Warren Foust, new equity awards including restricted stock units (RSUs) and stock options. A significant portion of these awards, specifically performance stock options for 255,489 shares, are tied to stock-price hurdles of $50.00, $75.00, and $100.00 per share, alongside time-based vesting. Additionally, 22,493 RSUs and other time-based stock options were granted, with some performance stock units from an earlier program also vesting and shares withheld for tax purposes.
Why STAAR Surgical (STAA) Shares Are Sliding Today
STAAR Surgical (NASDAQ:STAA) shares fell 8.3% after investors reacted negatively to mixed guidance following its Q2 earnings report, despite exceeding sales and EPS estimates. Stifel lowered its price target on STAA to $28 from $31, maintaining a Hold rating due to concerns about the "fragile" refractive market in China. The stock's current performance reflects investor concern over broader market conditions and recent industry warnings about potential slowdowns in medical procedures.
Stifel cuts Staar Surgical stock price target on China concerns
Stifel has lowered its price target for Staar Surgical Company (NASDAQ:STAA) to $28 from $31, while maintaining a Hold rating, citing concerns related to the China market despite positive aspects highlighted in the company's recent earnings call. Although the company reported strong second-quarter revenue that surpassed expectations, particularly from China, its earnings per share fell short of analyst projections. Other analysts, including Jefferies and Piper Sandler, have also adjusted their price targets or reiterated ratings, reflecting a cautious but not entirely negative outlook on the stock.
Stifel cuts Staar Surgical stock price target on China concerns
Stifel has lowered its price target for Staar Surgical Company (NASDAQ:STAA) to $28 from $31, while maintaining a Hold rating, citing concerns about the China market despite the company's strong second-quarter performance. The company's recent earnings call highlighted positive trends including China share gains and EVO+ momentum, and it comfortably aligns with Street estimates for Q3 and fiscal year 2026 revenue. Despite robust growth in China contributing significantly to revenue, the firm noted that the China refractive end market still appears fragile.
STAAR Surgical (NASDAQ:STAA) Shares Down 6.6% Following Analyst Downgrade
STAAR Surgical (NASDAQ:STAA) shares dropped 6.6% after Stifel Nicolaus lowered its price target from $31 to $28 while maintaining a hold rating. The company's stock now has a consensus "Hold" rating and an average price target of $28.40 from analysts. Despite exceeding revenue expectations with $93.53 million, the company missed earnings estimates, reporting $0.16 EPS against an expected $0.22.
Why STAAR Surgical (STAA) Is Up 8.1% After Returning To Profit Under New CEO Warren Foust – And What's Next
STAAR Surgical (STAA) reported a significant return to profitability in Q2 2026 with sales of US$93.54 million and net income of US$8.06 million, reversing previous losses. This turnaround coincides with Warren Foust's appointment as CEO, leading to a positive market reaction with the stock up 8.1%. The company's future investment narrative focuses on the sustainability of these improved volumes and margins, especially concerning inventory management in China and global growth.
STAAR Surgical (STAA) Gives Warren Foust The CEO Role After Its Profit Reset
STAAR Surgical has appointed Warren Foust as its permanent President and CEO, following a period of operational reset and a return to profitable growth under his interim leadership. Foust's promotion from COO and interim co-CEO signifies a defined leadership direction for the ophthalmic device maker. Investors will be watching for sustained profitability, China revenue trends, and EVO+ uptake to assess the success of this leadership change.
Quantinno Capital Management LP Takes $1.11 Million Position in STAAR Surgical Company $STAA
Quantinno Capital Management LP has acquired a new position in STAAR Surgical Company, purchasing 59,302 shares valued at approximately $1.11 million. This makes Quantinno Capital Management LP a 0.12% stakeholder in the company, which has seen its revenue increase by 111.1% year-over-year in the latest quarter, though its earnings per share missed analyst expectations. Institutional investors and hedge funds now collectively own 96.70% of STAAR Surgical, with analyst sentiment remaining mixed with an average "Hold" rating.
Staar Surgical Co (STAA) Shares Surge 3.4% -- What GF Score of 80 Tells Investors
Staar Surgical Co (STAA) shares surged 3.4% to $26.19, with a GF Score of 80/100, indicating strong overall performance. The stock is considered "Modestly Undervalued" by GuruFocus, with a potential upside of 21.8% from its current price, although its high P/E ratio and lack of profitability warrant caution for investors. Four gurus have increased their stakes, and there have been no insider transactions in the last three months, suggesting confidence in the company's long-term value.
STAAR Surgical (STAA) reports 8.4% stake held by Madison Avenue group
A group of investment entities associated with Eli Samaha, collectively known as the Madison Avenue group, has reported a beneficial ownership of 8.4% in STAAR Surgical Company (STAA) as of June 30, 2026. This stake represents 4,175,748 shares of Common Stock out of 49,788,495 shares outstanding. The filing indicates shared voting and dispositive power among Madison Avenue International LP, Madison Avenue Partners, LP, EMAI Management, LLC, Madison Avenue GP, LLC, Caraway Jackson Investments LLC, and Eli Samaha.
UBS Adjusts Price Target on STAAR Surgical to $19 From $20, Keeps Sell Rating
UBS has adjusted its price target for STAAR Surgical Company (STAA) to $19, down from $20, while maintaining a Sell rating on the stock. This update reflects the analyst's current outlook on the medical equipment company. The article also notes recent company activities including Q2 2026 earnings results and leadership appointments.
STAAR Surgical (STAA) Stock Price Shrugs Off Profit Rebound As China Dominates
STAAR Surgical reported a strong Q2 2026, returning to profit with $8.1 million in net income and $93.5 million in sales, largely driven by significant growth in China. Despite these positive results, the stock price barely moved, reflecting investor concerns about the company's heavy reliance on the China market and a single product category, as well as unresolved geopolitical and supply chain risks. The article highlights both the bullish case, centered on China's contribution to profitability, and the bearish concerns regarding durability and diversification.
Jefferies cuts STAAR Surgical stock price target on estimate update
Jefferies has lowered its price target for STAAR Surgical (NASDAQ:STAA) to $28 from $29, while maintaining a Hold rating, following the company's second-quarter 2026 results. STAAR Surgical reported Q2 revenue of $93.5 million, beating consensus estimates, with strong China sales, but missed earnings per share expectations at $0.16 versus $0.22. Despite the earnings miss, the company showed robust sales growth, particularly in China, and solid financial flexibility.
STAAR Surgical Company Q2 2026 Earnings Call Summary
STAAR Surgical reported record first-half revenue, driven by the successful launch of EVO Plus in China, which helped gain market share despite a challenging refractive market. The company is strategically shifting to a platform approach, with plans for new product development and a transition to 100% Swiss manufacturing for China-bound products by late 2026 to mitigate tariff impacts. Management remains confident in its long-term growth trajectory, emphasizing lens-based surgery's advantages and targeting over $200 million in cash with no debt by year-end 2026.
STAAR Surgical Company Stock 12‑Month Price Target Cut to $28.89, Implies 14% Upside
STAAR Surgical Company's average 12-month price target has been reduced to $28.89 from $29.33, according to estimates from 9 analysts. This updated target suggests a potential upside of approximately 14% based on the August 12 closing price. The consensus rating for the stock remains "Hold" among 11 analysts, with 2 recommending "Buy", 8 "Hold", and 1 "Sell".
Piper Sandler reiterates Neutral on STAAR Surgical stock at $33
Piper Sandler reiterated a Neutral rating on STAAR Surgical (NASDAQ:STAA) with a $33.00 price target, following the company's second-quarter results. While STAAR Surgical's China business exceeded expectations, generating $52.3 million in revenue, the company missed revenue expectations in other key regions like the United States. Despite overall revenue growth of 51.3% and a significant 57.8% return over the last six months, concerns remain regarding underlying visibility across different geographies.
STAAR Surgical (NASDAQ:STAA) Price Target Lowered to $37.00 at Wedbush
Wedbush has lowered its price target for STAAR Surgical (NASDAQ:STAA) to $37.00 from $40.00 but maintained an "outperform" rating, indicating a potential upside of 45.61%. Despite this, analyst sentiment is mixed, with an average "hold" rating and a consensus price target of $26.61. The company recently exceeded quarterly revenue and EPS estimates, reporting $93.52 million in revenue and $0.10 EPS, with revenue growing 119.6% year over year.
STAAR Surgical: China Generates More Than Half Of Q2 Revenue As Total Sales Jump 111%
STAAR Surgical reported a 111% year-over-year jump in Q2 2026 net sales to $93.5 million, with China contributing over half of this revenue at $52.3 million. The company saw significant profitability improvements, including a gross margin increase to 74.5% and net income of $8.1 million. STAAR Surgical attributes its growth to strong demand for ICL procedures in key markets, especially China, and expects continued market share gains and product innovation.
STAAR Surgical Q2 Sales Surge, Fueled by China as Key Market
STAAR Surgical (NASDAQ: STAA) announced significant Q2 2026 financial results, with net sales reaching $93.5 million, an 111 percent increase year-over-year. This surge was primarily driven by the Chinese market, which accounted for over half of the quarterly revenue. The company also reported improvements in gross margin and net income, alongside double-digit growth in the Americas and EMEA regions (excluding the Middle East).
STAAR Surgical (NASDAQ:STAA) Delivers Strong Q2 CY2026 Numbers But Stock Drops
STAAR Surgical (NASDAQ:STAA) reported strong Q2 CY2026 results, with revenue up 111% year-on-year to $93.54 million, exceeding analyst expectations, and GAAP EPS of $0.16, beating estimates by 12.6%. Despite these positive numbers, the stock dropped 8% immediately after the announcement. The company's operating margin saw a significant increase, and analysts anticipate substantial EPS growth for the full year.
Earnings Flash (STAA) STAAR Surgical Company Reports Q2 Revenue $93.5M, vs. FactSet Est of $90.6M
STAAR Surgical Company (STAA) reported its Q2 revenue of $93.5 million, surpassing FactSet's estimate of $90.6 million. This financial update indicates a positive performance for the medical equipment company during the second quarter. The article provides a brief overview of the company's recent earnings.
Defender Capital LLC. Has $12.37 Million Position in STAAR Surgical Company $STAA
Defender Capital LLC. reduced its stake in STAAR Surgical Company (NASDAQ:STAA) by 33.1% in the second quarter, now holding 431,187 shares valued at $12.37 million, which represents 4% of its portfolio. STAAR Surgical reported strong Q2 earnings, beating analyst expectations with EPS of $0.10 and revenue of $93.52 million, marking a 119.6% year-over-year increase. Despite mixed analyst sentiment resulting in a consensus "Hold" rating, institutional investors own a significant 96.7% of the stock.
What To Expect From STAAR Surgical’s (STAA) Q2 Earnings
STAAR Surgical (STAA) is set to report its Q2 earnings this Wednesday after market hours. Analysts expect a 104% year-on-year revenue growth, a significant reversal from the previous year's decline. Despite past revenue misses, analysts have reconfirmed their estimates, though STAA's share price has recently underperformed its peers in the medical devices & supplies segment.
How Investors Are Reacting To STAAR Surgical (STAA) Formalizing Warren Foust’s CEO Role And Leadership Structure
STAAR Surgical (STAA) recently formalized Warren Foust's role as President, CEO, and director, with Deborah Andrews continuing as EVP and CFO, consolidating leadership. This move is seen as reinforcing investor confidence, as Foust is credited with an operational reset and return to profitable growth. The article discusses how this change influences STAAR's investment narrative, including the FDA's expanded age indication for its implantable lenses and the ongoing challenges in the China market.
How Investors Are Reacting To STAAR Surgical (STAA) Formalizing Warren Foust’s CEO Role And Leadership Structure
STAAR Surgical (STAA) recently formalized Warren Foust's role as President, CEO, and director, with Deborah Andrews becoming Executive Vice President and CFO, solidifying a leadership structure that was previously interim. This move is seen as reinforcing investor confidence by consolidating control under a leader credited with operational improvements and a return to profitable growth. While the FDA's expanded age indication for EVO/EVO+ Visian ICLs broadens the U.S. patient pool, the company still faces challenges in China and questions about its heavy reliance on ICL technology.
Form 8K STAAR Surgical Company For: 6 August By Investing.com
This article announces the filing of a Form 8K by STAAR Surgical Company on August 6th. The brief piece from Investing.com indicates that the Form 8K is publicly available for review. The publication also provides various market data and other news headlines.
STAAR Surgical (NASDAQ: STAA) names Warren Foust chief executive
STAAR Surgical has appointed Warren Foust as President and Chief Executive Officer, effective August 4, 2026. Foust previously served as Interim Co-CEO, President, and COO, and his compensation package includes a base salary of $730,000, a significant cash bonus target, and substantial equity grants tied to share-price hurdles. Deborah Andrews will transition from Interim Co-CEO to Executive Vice President and Chief Financial Officer, receiving new equity awards aligned with her expanded role.
Is STAAR Surgical (STAA) Undervalued After Naming A New CEO?
STAAR Surgical (STAA) recently appointed Warren Foust as its new CEO, drawing investor attention despite recent share price declines. While analysts set a consensus price target of $29.67, indicating the stock is undervalued, key risks such as reliance on a single distributor in China and competitive pressures remain. The article suggests investors should analyze the underlying data and not solely rely on headlines.
Staar Surgical (STAA) Upgraded to Strong Buy: What Does It Mean for the Stock?
Staar Surgical (STAA) has been upgraded to a Zacks Rank #1 (Strong Buy), indicating an upward trend in its earnings estimates. This upgrade suggests positivity about its earnings outlook, which could lead to increased buying pressure and a rise in its stock price. The Zacks rating system is highly regarded for its correlation with near-term stock price movements, with #1 ranked stocks generating an average annual return of +25% since 1988.
STAAR Surgical Names Warren Foust as Permanent CEO
STAAR Surgical has appointed Warren Foust as its permanent President and CEO, effective August 4, 2026. Foust previously served as interim co-CEO, president, and COO since February 2026. The company recently expanded the FDA approval for its EVO/EVO+ Visian Implantable Collamer Lenses for patients aged 21 to 60.
STAAR Surgical appoints Warren Foust as permanent CEO
STAAR Surgical has appointed Warren Foust as its permanent CEO, following a period of leadership uncertainty after the collapse of Alcon's $1.6 billion takeover bid. Foust, who previously served as interim co-CEO and president, will continue as president, while Deborah Andrews resumes her role as CFO. This decision comes after a rigorous global search overseen by a five-person committee, and Foust will lead the company after it reported record net sales of $93.5 million in the first quarter of 2026.
Staar Surgical Appoints Warren Foust as President and CEO
Staar Surgical has appointed Warren Foust as its new President, CEO, and a member of the board of directors, effective August 4, 2026. Foust previously served as interim co-CEO, president, and chief operating officer. Deborah Andrews will transition to executive vice president while retaining her role as chief financial officer.
Warren Foust Named President and CEO of STAAR Surgical, Deborah Andrews Transitions to Executive Vice President and CFO Roles
STAAR Surgical Company has appointed Warren Foust as its new President, Chief Executive Officer, and a board member, effective August 4, 2026. Foust previously served as interim co-CEO, president, and chief operating officer. Deborah Andrews, who served as interim co-CEO alongside Foust, will transition to Executive Vice President and continue as Chief Financial Officer, effective the same date. The appointments follow a rigorous global search and aim to drive STAAR Surgical's continued growth and innovation in refractive surgery.
STAAR Surgical Reports More Than 4M Lenses Sold as CEO Changes
STAAR Surgical announced the appointment of Warren Foust as President and Chief Executive Officer, effective August 4, 2026, following an extensive global search. Foust, who previously served as Interim Co-CEO and President & Chief Operating Officer, will focus on revenue growth, profit expansion, and innovation acceleration. Deborah Andrews will continue as Executive Vice President and Chief Financial Officer, and the company highlighted achieving its strongest first half in history and exceeding 4 million lenses sold globally.
STAAR Surgical names Warren Foust CEO, Andrews to EVP and CFO
STAAR Surgical Company has appointed Warren Foust as President and CEO, and a new member of its Board of Directors, effective immediately. Deborah Andrews, who served as Interim Co-CEO alongside Foust, will now serve as Executive Vice President while continuing her role as Chief Financial Officer. These appointments follow an extensive global search for permanent leadership for the company, which manufactures phakic intraocular lenses.
STAAR Surgical to discuss vision correction business Aug. 12
STAAR Surgical (NASDAQ: STAA) announced it will release its second-quarter 2026 financial results and a shareholder letter on August 12, 2026, after market close. The company will also host an earnings call and webcast at 5:30 p.m. ET to discuss its financial performance, operational execution, strategic priorities, and market dynamics in key regions like China and the United States. This event will cover topics such as revenue growth, profit expansion, and innovation acceleration related to its EVO ICL™ vision correction technology.
STAAR Surgical Company Revenue Breakdown – NASDAQ:STAA
This article provides a breakdown of STAAR Surgical Company's (NASDAQ: STAA) revenue. Last year, the company generated $239.44 million USD, with its top-performing segment, Non-consignment, contributing $178.99 million USD. The "Other" segment accounted for $93.84 million USD last year.
How (STAA) Movements Inform Risk Allocation Models
This article analyzes Staar Surgical Company (NASDAQ: STAA) movements, highlighting weak near and mid-term sentiment, but a neutral long-term outlook. It presents AI-generated institutional trading strategies for various risk profiles, including position trading, momentum breakout, and risk hedging. The analysis also provides multi-timeframe signal analysis with support and resistance levels.
STAAR Surgical Co (STAA) Institutional Confidence
STAAR Surgical Co (STAA) has an institutional shareholding score of 10.00, placing it first among 199 companies in the Healthcare Equipment & Supplies industry. Institutional shareholding increased by 10.75% quarter-over-quarter, with Steven Cohen being the largest institutional shareholder despite a decrease in his holdings. Several other institutions, including Broadwood Capital and BlackRock, also hold significant shares.
UBS Initiates STAAR Surgical at Sell With $20 Price Target
UBS has initiated coverage on STAAR Surgical (STAA) with a "Sell" rating and a price target of $20. This rating suggests a negative outlook for the medical equipment company. The article also mentions recent news and analyst updates regarding STAAR Surgical's performance, particularly in China.
STAAR Surgical Company Revenue Breakdown – BX:SR3
STAAR Surgical Company (SR3) reported total revenue of 189.82 million CHF last year. Its top-performing segment, Non-consignment, contributed 141.90 million CHF, while "Other" accounted for 74.39 million CHF. The company's financial data is available on TradingView, detailing segments and regional performance.
STAAR Surgical Co (STAA) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of STAAR Surgical Co (STAA), listing its major shareholders and their proportional holdings. It also provides a breakdown of shareholder types, institutional shareholding trends over several quarters, and recent shareholder activities including changes in holdings by key investors.
STAAR Surgical Co (STAA) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of STAAR Surgical Co (STAA) focusing on its dividend and stock split history. It notes that the company has not distributed any dividends over the past five years. The page includes current stock data and general company information but lacks specific dividend dates or stock split events.
Can STAAR Surgical (STAA) Justify Its Valuation As Sales Guidance Tops $90 Million?
STAAR Surgical (STAA) has guided Q2 2026 net sales to over $90 million, significantly up from $44.3 million a year prior, making revenue momentum a key discussion point for investors. Despite a recent stock drop, its fair value is pegged at $29.67, above its last close of $23.38, driven by significant cash reserves and no debt. However, a high P/S ratio compared to industry averages and reliance on a single Chinese distributor could pose valuation risks.
STAAR Surgical Company Revenue Breakdown – FWB:SR3
This article provides a revenue breakdown for STAAR Surgical Company (FWB:SR3). It highlights that last year the company generated €203.87 million, with the "Non-consignment" segment contributing the most at €152.40 million. The "Other" category also made a significant contribution, accounting for €79.90 million last year.
Did STAAR Surgical’s Surging Q2 2026 Revenue Guidance Just Shift STAAR Surgical’s (STAA) Investment Narrative?
STAAR Surgical announced significantly raised revenue guidance for Q2 2026, expecting net sales to exceed US$90 million compared to US$44.3 million in Q2 2025. This surge, potentially driven by the FDA's expanded age indication for EVO ICLs, suggests strong business momentum and could reshape the company's investment narrative. However, the article also highlights ongoing risks related to China exposure and dependence on a single distributor model.
